Views & Analysis Chiesi ups its focus on rare diseases Italy’s Chiesi has created a new business unit aimed at increasing its presence in the market for rare disease drugs.
News Chiesi starts rare diseases division, ahead of potential Fab... Italian pharma Chiesi has begun a new rare diseases division as it builds towards a potential commercial launch for its Fabry Disease therapy.
News FDA rejection scuppers AZ’s hopes of a COPD triple clash wit... The FDA has just handed an advantage to GlaxoSmithKline’s triple therapy for chronic obstructive pulmonary disease (COPD) by
Market Access Verona to take COPD hopeful into phase 3 Verona Pharma is to take lung drug RPL554 into late clinical development after a successful phase 2b trial.
News Europe: thumbs up for Roche's Hemlibra, Chiesi rare disease ... Drug has been approved in US since November
News EU regulators back Chiesi drug for rare inherited disease Decision paves way for licence to treat alpha-mannosidosis,
Oncology ASCO 2026: Chinese firms take a front seat in oncology, with... Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
